Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Second Generation Dutasteride/Tamsulosin in Fed State
NCT02058576Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dutasteride and tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoints: Pharmacokinetic profile for second generation dutasteride at 72 hours and Composite of PK parameters for tamsulosin HCL at 72 hours. Started Feb 2014; status: completed.
02
Drugs
dutasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02058576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058576.